MRD as a marker for depth of remission in CLL
In this interview, Peter Hillman, MD, ChB, from Leeds Teaching Hospital NHS Trust, Leeds, UK, details the importance of measurable residual disease (MRD) as a sensitive, quick and efficient measure to...
Author: VJHemOnc
Added: 06/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Hospitals | Teaching | Teaching Hospitals | Universities & Medical Training